TY - JOUR
T1 - Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management
T2 - A Review on the Recent Update
AU - Anand, Uttpal
AU - Jakhmola, Shweta
AU - Indari, Omkar
AU - Jha, Hem Chandra
AU - Chen, Zhe Sheng
AU - Tripathi, Vijay
AU - Pérez de la Lastra, José M.
N1 - Funding Information:
We thank the Department of Biotechnology and Ministry of Human Resource and Development, Govt. of India for the fellowship to Omkar Indari and Shweta Jakhmola, respectively, in the form of a research stipend. We gratefully acknowledge the Indian Institute of Technology Indore for providing facilities and support.
Funding Information:
This work was funded by “Agencia Canaria de Investigación, Innovación y Sociedad de la Información (ACIISI) del Gobierno de Canarias”, project ProID2020010134 “Bioprospección y biotecnologıá en el descubrimiento de péptidos antimicrobianos contra patógenos resistentes” and CajaCanarias, project 2019SP43. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Publisher Copyright:
© Copyright © 2021 Anand, Jakhmola, Indari, Jha, Chen, Tripathi and Pérez de la Lastra.
PY - 2021/6/30
Y1 - 2021/6/30
N2 - Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID-19) worldwide. Wuhan, a city in China became the epicenter of the outbreak of COVID-19 in December 2019. The disease was declared a pandemic globally by the World Health Organization (WHO) on 11 March 2020. SARS-CoV-2 is a beta CoV of the Coronaviridae family which usually causes respiratory symptoms that resemble common cold. Multiple countries have experienced multiple waves of the disease and scientific experts are consistently working to find answers to several unresolved questions, with the aim to find the most suitable ways to contain the virus. Furthermore, potential therapeutic strategies and vaccine development for COVID-19 management are also considered. Currently, substantial efforts have been made to develop successful and safe treatments and SARS-CoV-2 vaccines. Some vaccines, such as inactivated vaccines, nucleic acid-based, and vector-based vaccines, have entered phase 3 clinical trials. Additionally, diverse small molecule drugs, peptides and antibodies are being developed to treat COVID-19. We present here an overview of the virus interaction with the host and environment and anti-CoV therapeutic strategies; including vaccines and other methodologies, designed for prophylaxis and treatment of SARS-CoV-2 infection with the hope that this integrative analysis could help develop novel therapeutic approaches against COVID-19.
AB - Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID-19) worldwide. Wuhan, a city in China became the epicenter of the outbreak of COVID-19 in December 2019. The disease was declared a pandemic globally by the World Health Organization (WHO) on 11 March 2020. SARS-CoV-2 is a beta CoV of the Coronaviridae family which usually causes respiratory symptoms that resemble common cold. Multiple countries have experienced multiple waves of the disease and scientific experts are consistently working to find answers to several unresolved questions, with the aim to find the most suitable ways to contain the virus. Furthermore, potential therapeutic strategies and vaccine development for COVID-19 management are also considered. Currently, substantial efforts have been made to develop successful and safe treatments and SARS-CoV-2 vaccines. Some vaccines, such as inactivated vaccines, nucleic acid-based, and vector-based vaccines, have entered phase 3 clinical trials. Additionally, diverse small molecule drugs, peptides and antibodies are being developed to treat COVID-19. We present here an overview of the virus interaction with the host and environment and anti-CoV therapeutic strategies; including vaccines and other methodologies, designed for prophylaxis and treatment of SARS-CoV-2 infection with the hope that this integrative analysis could help develop novel therapeutic approaches against COVID-19.
KW - COVID-19
KW - antibodies
KW - peptide
KW - therapeutic targets
KW - treatment
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85110120018&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2021.658519
DO - 10.3389/fimmu.2021.658519
M3 - Review article
C2 - 34276652
AN - SCOPUS:85110120018
SN - 1664-3224
VL - 12
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 658519
ER -
